The aim of this work is to evaluate the success rate of including medicinal products to the reimbursement system after the adoption of new drug legislation in December 2011.
Reasons for rejections of submissions
In the case of all unsuccessful submissions, in 59% the reason for non-inclusion was the pharmacoeconomic analysis and the most common shortcomings concerned the selection of analysis (14%), selection of comparator (12%) and incorrect calculation of output parameters (12%). Other most frequent reasons were low efficacy, conditional EMA registration, formal shortcomings, and incorrect reference price. In the case of new drugs, which were not included to the reimbursement list, in 64% of cases the reason for non-inclusion was the pharmacoeconomic analysis ( Figure 3 ).
METHODS
In Slovakia, drugs included in Reimbursed List are standardly reimbursed from public health insurance. We assessed the inclusion of medicinal products to the reimbursement system based on data published on the Ministry of Health website (application forms A1N, A1P)
1
. The success rate of submissions was evaluated by Pharm-In on-line application eRiX 2 . We evaluated the success rate of reimbursement applications for drugs in the period from 1.12.2011 to 30.6.2015. Only submissions initiated by manufacturers with published 1 st degree decision were included to the analysis. Submissions of more packs of one drug (e.g. different strengths or pack sizes of one drug) were evaluated as one "submission". If the first submission was not successful, there are some cases with more than one submission for the same drug. The analysis was performed separately also for inclusion of new substances, regardless the repeated submissions, which have not been listed before in the Reimbursement List (bellow as "new" drugs). This "new drug" analysis was performed in order to evaluate if the new drug was included to Reimbursement List at all, regardless of the number of repeated submissions. We analysed separately the successful and unsuccessful submissions, the success rate of submissions in individual therapeutic groups, as well as the development of the success rate of the inclusion of drugs over the monitored period. With unsuccessful submissions, we assessed the shortcomings in pharmacoeconomic analyses given in the decisions. The methodology and correctness of data presented in submissions, or the fairness of approval process, were not assessed in the analysis.
RESULTS

General analysis of submissions
During December 2011 to June 2015 the success rate of inclusion of drugs to the reimbursement system had an increasing trend. While in 2012, 56% of submissions were successful, in 2013 it was 62% of submissions, 85% in 2014 and 77% in 2015 (until June 2015 . In the evaluated period a total of 178 submissions (172 A1N and 6 A1P) were registered for the inclusion of drugs to the reimbursement system. Totally, 57 new active substances were evaluated in 79 submissions, with average number of submissions 1.4 (Table 1 and 2). The remainder of submissions were comprising fixed combinations (48), new strengths (25), forms (23) and packaging (3). Out of all 178 submissions, 55 cases (30.9%) concerned drugs that in the Budget impact analysis had shown the need for an increase in expenditure (Figure 1 and 2) . 
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Figure 2. Overview of successful submissions (new drugs included in Reimbursement List)
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Success rate of submissions
In period of December 2011 to June 2015, out of all 178 submissions, 127 were successfully included to the Reimbursement List (71%), 51 submissions were unsuccessful (29%) (Fig. 1) . In A1N submissions (standard reimbursement), the success rate was 72%, in A1P (conditional reimbursement) it was 67%. In successful submissions, there were 33 submissions showing the need for an increase in expenditure (26%) and 94 with no additional budget impact (74%) (Figure 1) . In unsuccessful cases it was 22 (43%) and 29 submissions (57%). In the case of applications with budget impact, the success rate was 60%. Success rate of submissions which included Cost Minimization Analysis was 76%, success rate of submissions which contained Cost Utility Analysis or Cost Effectiveness Analysis was 65%. The highest inclusion success rate was seen for drugs from the anatomic therapeutic groups (ATC) groups M, V and D, while the lowest was the drugs listed in groups H, L and S. 
